Median cost-effectiveness (net cost per DALY averted) by 10-country increments in order of cost-effectiveness
| Countries ranked by IPC cost-effectiveness | Campaign 1 | Campaign 2 | Antiretroviral therapy for HIV |
|---|---|---|---|
| Top 10 | US$50 | US$102 | US$854 |
| 11–20 | US$88 | US$141 | US$958 |
| 11–30 | US$121 | US$197 | US$797 |
| 31–40 | US$185 | US$318 | US$894 |
| 41–50 | US$335 | US$591 | US$683 |
| 51–60 | US$1721 | US$3514 | US$666 |
| 61–70 | US$4774 | US$17 068 | US$587 |
DALY, disability-adjusted life-year.